South Korea · Delayed Price · Currency is KRW GC Biopharma Statistics
Total Valuation
GC Biopharma has a market cap or net worth of KRW 1.53 trillion. The enterprise value is 2.68 trillion.
| Market Cap | 1.53T |
| Enterprise Value | 2.68T |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
GC Biopharma has 11.41 million shares outstanding. The number of shares has increased by 0.24% in one year.
| Current Share Class | 11.41M |
| Shares Outstanding | 11.41M |
| Shares Change (YoY) | +0.24% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 16.59% |
| Float | 5.45M |
Valuation Ratios
The trailing PE ratio is 27.24 and the forward PE ratio is 22.69.
| PE Ratio | 27.24 |
| Forward PE | 22.69 |
| PS Ratio | 0.79 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 1.78 |
| P/FCF Ratio | 42.48 |
| P/OCF Ratio | 16.70 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.62, with an EV/FCF ratio of 74.20.
| EV / Earnings | 47.53 |
| EV / Sales | 1.38 |
| EV / EBITDA | 14.62 |
| EV / EBIT | 28.16 |
| EV / FCF | 74.20 |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.69.
| Current Ratio | 1.18 |
| Quick Ratio | 0.49 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | 7.25 |
| Debt / FCF | 28.35 |
| Interest Coverage | 1.11 |
Financial Efficiency
Return on equity (ROE) is 2.28% and return on invested capital (ROIC) is 1.35%.
| Return on Equity (ROE) | 2.28% |
| Return on Assets (ROA) | 1.11% |
| Return on Invested Capital (ROIC) | 1.35% |
| Return on Capital Employed (ROCE) | 2.76% |
| Revenue Per Employee | 947.30M |
| Profits Per Employee | 27.59M |
| Employee Count | 2,042 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.84 |
Taxes
| Income Tax | -3.94B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.63% in the last 52 weeks. The beta is 0.91, so GC Biopharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | -4.63% |
| 50-Day Moving Average | 132,548.00 |
| 200-Day Moving Average | 130,941.50 |
| Relative Strength Index (RSI) | 53.04 |
| Average Volume (20 Days) | 55,927 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GC Biopharma had revenue of KRW 1.93 trillion and earned 56.34 billion in profits. Earnings per share was 4,929.94.
| Revenue | 1.93T |
| Gross Profit | 533.92B |
| Operating Income | 53.03B |
| Pretax Income | 30.46B |
| Net Income | 56.34B |
| EBITDA | 141.16B |
| EBIT | 53.03B |
| Earnings Per Share (EPS) | 4,929.94 |
Balance Sheet
The company has 68.52 billion in cash and 1.02 trillion in debt, giving a net cash position of -954.40 billion or -83,622.65 per share.
| Cash & Cash Equivalents | 68.52B |
| Total Debt | 1.02T |
| Net Cash | -954.40B |
| Net Cash Per Share | -83,622.65 |
| Equity (Book Value) | 1.49T |
| Book Value Per Share | 113,843.54 |
| Working Capital | 223.61B |
Cash Flow
In the last 12 months, operating cash flow was 91.80 billion and capital expenditures -55.72 billion, giving a free cash flow of 36.08 billion.
| Operating Cash Flow | 91.80B |
| Capital Expenditures | -55.72B |
| Free Cash Flow | 36.08B |
| FCF Per Share | 3,161.47 |
Margins
Gross margin is 27.60%, with operating and profit margins of 2.74% and 2.91%.
| Gross Margin | 27.60% |
| Operating Margin | 2.74% |
| Pretax Margin | 1.57% |
| Profit Margin | 2.91% |
| EBITDA Margin | 7.30% |
| EBIT Margin | 2.74% |
| FCF Margin | 1.87% |
Dividends & Yields
This stock pays an annual dividend of 1,500.00, which amounts to a dividend yield of 1.16%.
| Dividend Per Share | 1,500.00 |
| Dividend Yield | 1.16% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 33.43% |
| Buyback Yield | -0.24% |
| Shareholder Yield | 0.92% |
| Earnings Yield | 3.68% |
| FCF Yield | 2.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 7, 2013. It was a forward split with a ratio of 1.05.
| Last Split Date | Jun 7, 2013 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
GC Biopharma has an Altman Z-Score of 1.69 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.69 |
| Piotroski F-Score | 6 |